Oxidative Medicine and Cellular Longevity / 2017 / Article / Tab 1 / Review Article
P-glycoprotein (ABCB1) and Oxidative Stress: Focus on Alzheimer’s Disease Table 1 Summary of (a) in vitro and (b) in vivo studies and (c) clinical trials on neuroprotective activity of compounds that targeted Aβ transport across the blood-brain barrier mediated by ABCB1.
(a) In vitro Treatment Dose Duration Cell line Species Reference Sulforaphane (SFN) 0.01–5 μ M 0–200 min Brain capillaries Nrf2−/− mouse [108 ] p53−/− mouse Oleocanthal (Oleo) 0.5–50 μ M 72 h bEnd3 Mouse [141 ] 1α ,25-Dihydroxyvitamin D3 (1,25(OH)2 D3) 1–100 nM 4 h or 24 h Brain capillaries Rat [145 ] 1–3 days RBE4 Rat hCMEC/D3 Human Fascalpsyn 1–100 μ M 24–48 h LS-180 Human [147 ] hGF
(b) In vivo Treatment Dose Duration Model Species Reference SFN 1–10 mg/kg intraperitoneal (i.p.) 2 days Sprague-Dawley Rat [108 ] Verapamil 2–5 mg/kg i.p. 21 days Streptozocin-induced sporadic dementia Rat [136 ] Berberine 25–100 mg/kg per oral (p.o.) 21 days α -Tocopherol36 mg/kg p.o. Lifespan Ttpa−/− APPsw Mouse [138 ] Pregnenolone-16α -carbonitrile 25 mg/kg i.p. 7 days APPsw/Tg2576 Mouse [114 ] Oleo 10 mg/kg/12 h i.p. 2 weeks C57BL/6 Mouse [141 ] Oleo 5 mg/kg/die i.p. 4 weeks TgSwDI Mouse [142 ] St. John’s wort 1250 mg/kg/die p.o. 60–120 days APP/PS+/− Mouse [143 ] 1,25(OH)2 D3 2.5 μ g/kg/die i.p. 8 days Fxr−/− Mouse [144 ] 1,25(OH)2 D3 2.5 μ g/kg/48 h i.p. 8 days Tg2576 Mouse [146 ] TgCRND8 Rivastigmine 0.3 mg/kg/day alzet pump 8 weeks APP+ /mdr1 Mouse [148 ]
(c) Clinical trialsTreatment Dose Duration Diagnosis Reference Rifampin 300 mg/die p.o. 12 months AD [140 ] Doxycyclin 200 mg/die p.o.